WO2003066094A3 - Hepatitis b vaccines - Google Patents

Hepatitis b vaccines Download PDF

Info

Publication number
WO2003066094A3
WO2003066094A3 PCT/EP2003/001214 EP0301214W WO03066094A3 WO 2003066094 A3 WO2003066094 A3 WO 2003066094A3 EP 0301214 W EP0301214 W EP 0301214W WO 03066094 A3 WO03066094 A3 WO 03066094A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
vaccines
free
thiomersal
vaccine
Prior art date
Application number
PCT/EP2003/001214
Other languages
French (fr)
Other versions
WO2003066094A2 (en
Inventor
Koen De-Heyder
Peter Schu
Michelle Serantoni
Omer Van-Opstal
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Koen De-Heyder
Peter Schu
Michelle Serantoni
Omer Van-Opstal
Jean Stephenne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Koen De-Heyder, Peter Schu, Michelle Serantoni, Omer Van-Opstal, Jean Stephenne filed Critical Glaxosmithkline Biolog Sa
Priority to AU2003206862A priority Critical patent/AU2003206862A1/en
Publication of WO2003066094A2 publication Critical patent/WO2003066094A2/en
Publication of WO2003066094A3 publication Critical patent/WO2003066094A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to the use of a hepatitis B antigen free or substantially free of thiomersal, in the manufacture of a prophylactic or therapeutic hepatitis B vaccine for intradermal delivery.
PCT/EP2003/001214 2002-02-07 2003-02-05 Hepatitis b vaccines WO2003066094A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003206862A AU2003206862A1 (en) 2002-02-07 2003-02-05 Hepatitis b vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0202901.5 2002-02-07
GBGB0202901.5A GB0202901D0 (en) 2002-02-07 2002-02-07 Novel vaccine

Publications (2)

Publication Number Publication Date
WO2003066094A2 WO2003066094A2 (en) 2003-08-14
WO2003066094A3 true WO2003066094A3 (en) 2003-12-24

Family

ID=9930627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001214 WO2003066094A2 (en) 2002-02-07 2003-02-05 Hepatitis b vaccines

Country Status (3)

Country Link
AU (1) AU2003206862A1 (en)
GB (1) GB0202901D0 (en)
WO (1) WO2003066094A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292386A9 (en) * 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
BRPI0615420A2 (en) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic multiple vaccination including serogroup c meningococcus
EP1862176A1 (en) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Method for producing a vaccine composition
EP1862177A1 (en) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Method for producing a vaccine composition
CN102802662A (en) 2010-03-18 2012-11-28 诺华有限公司 Adjuvanted vaccines for serogroup B meningococcus
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (en) 2011-11-11 2014-12-24 Novartis Ag Fermentation medium, which is free of animal components, for the preparation of diphtheria toxoids for use in the vaccination of humans
DE102011118371B4 (en) 2011-11-11 2014-02-13 Novartis Ag Composition suitable for human vaccination, comprising a diphtheria toxoid, and process for its preparation
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
CN104159603A (en) 2012-03-08 2014-11-19 诺华股份有限公司 Combination vaccines with tlr4 agonists
RU2015106930A (en) 2012-09-06 2016-10-20 Новартис Аг COMBINED VACCINES WITH THE MENINGOCOCC SEROGRAPH B AND K / D / S
BR112015008040A2 (en) 2012-10-12 2017-07-04 Glaxosmithkline Biologicals Sa vaccine composition, combination vaccine, and processes for preparing an ap component and for manufacturing a vaccine composition
EP2934574A1 (en) 2012-12-18 2015-10-28 GlaxoSmithKline Biologicals SA Conjugates for protecting against diphtheria and/or tetanus
JP6475336B2 (en) * 2014-08-21 2019-02-27 チュン−アン ユニヴァーシティ インダストリー−アカデミー コーポレーション ファウンデーションＣｈｕｎｇ−Ａｎｇ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ rDNA NTS-based gene multiple insertion cassette set and GRAS grade recombinant yeast strain using the same
CN106222129A (en) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 A kind of cell culture medium improving antibody purity and cultural method
US20200158729A1 (en) * 2017-06-06 2020-05-21 Indevr, Inc. Simultaneous in vitro analysis of vaccine potency and toxin concentration
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
WO2002012287A1 (en) * 2000-08-10 2002-02-14 Glaxosmithkline Biologicals S.A. Purification of hbv antigens for use in vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
WO2002012287A1 (en) * 2000-08-10 2002-02-14 Glaxosmithkline Biologicals S.A. Purification of hbv antigens for use in vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G. SÖYLETIR ET AL.: "Clinical evaluation of low dose intradermally administered hepatis B vaccine: a comparison of plasma-derived and recombinant yeast-derived vaccines.", VACCINE, vol. 10, no. 5, 1992, GUILDFORD, GB, pages 301 - 304, XP002253769 *
K. PARFITT (EDITOR): "Martindale, the complete drug reference, thirty-second edition.", 1999, PHARMACEUTICAL PRESS, LONDON, XP002253770 *
L.K. BALL ET AL.: "AN ASSESSMENT OF THIMEROSAL USE IN CHILDHOOD VACCINES", PEDIATRICS, AMERICAN ACADEMY OF PEDIATRICS, EVANSTON, IL, US, vol. 107, no. 5, May 2001 (2001-05-01), pages 1147 - 1154, XP009001918, ISSN: 0031-4005 *

Also Published As

Publication number Publication date
GB0202901D0 (en) 2002-03-27
WO2003066094A2 (en) 2003-08-14
AU2003206862A1 (en) 2003-09-02
AU2003206862A8 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2003066094A3 (en) Hepatitis b vaccines
PT1361890E (en) Influenza vaccine formulations for intradermal delivery
WO2002087494A3 (en) Novel vaccine
EP1504112A4 (en) Development of a preventive vaccine for filovirus infection in primates
PL1635863T3 (en) Compositions to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
IL145982A0 (en) Vaccines
WO2003028760A3 (en) Vaccine
EP1594560A4 (en) Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
GB0025577D0 (en) Vaccine
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
MY126588A (en) Intranasal influenza virus vaccine
HK1168046A1 (en) Yeast-based vaccines as immunotherapy
EP1708748A4 (en) Influenza immunogen and vaccine
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2005120564A3 (en) Vaccine compositions and methods
AP2003002734A0 (en) Purification of HBV antigens for use in vaccines.
GB2444676A (en) Adjuvanted vaccine
WO2005072214A3 (en) Improved inactivated fcv vaccines
AU2003301850A8 (en) Hiv vaccine
AU2003294220A1 (en) Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
AU2003278175A8 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine
AU2002361682A1 (en) Innate immune system-directed vaccines
AU2003264724A1 (en) Flagellin peptides as adjuvants for vaccines
WO2004058188A3 (en) Vaccine compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP